Mnemo Therapeutics utilizes a novel approach to identify and target tumor-specific antigens that are shared across patients, enabling the development of personalized cancer therapies. This method addresses the challenge of limited druggable targets in oncology, enhancing treatment options for diverse patient populations.
Funding
$91.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of personalized cancer therapies is hindered by the limited availability of shared, druggable tumor-specific antigens across diverse patient populations. Traditional approaches often struggle to identify targets that are both specific to the tumor and present in a significant number of patients, limiting the applicability of targeted treatments.
Solution
Mnemo Therapeutics is developing a novel approach to identify and target tumor-specific antigens shared across patients, derived from previously unexplored regions of the genome. The company focuses on antigens arising from transposable elements and other non-coding regions, which are often dysregulated in cancer cells. By targeting these shared antigens, Mnemo aims to develop therapies applicable to a broader range of patients, overcoming the limitations of traditional personalized medicine approaches that rely on unique, patient-specific mutations. Their approach leverages the discovery of E-antigens, a class of tumor-specific targets derived from transposable element exonization, offering a new source of targets for immunotherapy and cell therapy.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer immunotherapies and cell therapies, as well as oncologists seeking more effective treatment options for their patients.
Features
- Identification of E-antigens, a novel class of shared tumor-specific antigens derived from transposable elements.
- Target discovery platform focused on previously unexplored regions of the genome.
- Focus on antigens presented on MHC class I molecules for T cell recognition.
- Development of both cell therapy and immunotherapy assets targeting these shared antigens.
- Identification of targets in solid tumors, including glioblastoma.
- Modulation of SUV39H1-mediated methylation to enhance CAR T cell function.